Clinical Trial Update: A Single-arm Evaluation of the Effect of HCV Treatment on Cardiovascular Disease Risk [Phase 4]

View source ↗

Summary

A Phase 4 single-arm study evaluating the effect of hepatitis C treatment on cardiovascular disease risk has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Snippet

Sponsor: University of California, Los Angeles | Conditions: Hepatitis C | Phase 4 | Status: WITHDRAWN